The idea to reduce expression of CLDN1 should also be considered in the context of the use of general DNA hypomethylating agents that are being used to reactivate tumor suppressor and pro-apoptotic genes and potentiate response to other cytotoxic chemotherapeutic agents, including in solid tumors. Here, CLDN1 is linked to neoplasm.